Fundraising Fox
🦊/Companies
Sign in

Eliem Therapeutics

NASDAQ: CLYM

Wilmington, US · Founded 2018 · Delaware corporation · 6 known investors

Find your way into Eliem Therapeutics

225 people in our graph share verified history with the Eliem Therapeutics team — schools, employers, funds. One of them is your warm intro.

Anthony Philippakisunlockedknows Erin Lavelle · together at Yale University (overlapped)
×8knows the team · via Amgen
×3knows the team · via Yale University

Eliem Therapeutics is a clinical-stage biotechnology company developing monoclonal antibodies targeting immune-mediated diseases, with budoprutug, an anti-CD19 antibody designed to deplete B cells in conditions including primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL antibody for IgA nephropathy and related B-cell mediated diseases.

Biotech

Founders & leadership

VMValerie Morisset
Valerie MorissetinEVP R&D and CSO2020–2024
EL
Erin LavelleinExecutiveErin Lavelle is an executive officer at Eliem Therapeutics with prior roles at ProfoundBio, Neoleukin Therapeutics, Alder Biopharmaceuticals, Amgen, and Merrill Lynch's Healthcare Investment Banking Division, including assignments in Asia; she holds a BA in Economics from Yale University and has expertise in capital raising, M&A, corporate finance, and general management in the life sciences sector.
RA
Robert AzelbyExecutive
JB
James BucherExecutive
LP
Leone PattersonNamed on SEC filing

Board

AR
Adam RosenbergBoard director
LRLiam Ratcliffe
Liam RatcliffeinBoard directorGeneral Partner at New Leaf Venture Partners
ALAndrew Levin
Andrew LevinBoard directorPartner at RA Capital
ST
Stephen ThomasBoard director
ST
Simon TateBoard director
AB
Aoife BrennanBoard director
JD
Judith DunnBoard director

Investors · 6

Manta Ray VenturesLondon
Access BiotechnologyreportedNew York City
ACORN BIOVENTURESreportedNew York
RA Capitalreported · 2 sourcesBoston

Also in the syndicate · 2

LifeArcSamlyn Capital

Reported raises · per SEC filings

Form D private placements

$363.2M disclosed across 7 rounds · 2019–2026

▶$110.1MraisedMay 2026 · 22 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Aoife BrennanExecutive Officer, Director
  • Perrin WilsonExecutive Officer
  • Stephen ThomasDirector
  • Douglas WilliamsDirector
  • Susan AltschullerExecutive Officer
  • Kimberlee DrapkinDirector
  • Alexander (Bo) ComboDirector
  • Judith DunnDirector
  • Andrew LevinDirector
Offering amount
$110.1M
Amount sold
$110.1M
Sales commissions
$6.3M
Placement agents
BTIG, LLC, Raymond James & Associates, Inc., Piper Sandler and Co., Robert W. Baird & Co. Incorporated, H.C. Wainwright & Co., LLC, Leerink Partners LLC
First sale
Apr 2026
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$41.9MraisedJul 2024 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Judith DunnDirector
  • Stephen ThomasDirector
  • Andrew LevinExecutive Officer, Director
  • Adam RosenbergDirector
  • Aoife BrennanExecutive Officer, Director
  • Liam RatcliffeDirector
  • Valerie MorissetExecutive Officer
  • Simon TateDirector
Offering amount
$41.9M
Amount sold
$41.9M
First sale
Jun 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$120MraisedJul 2024 · 8 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Adam RosenbergDirector
  • Stephen ThomasDirector
  • Liam RatcliffeDirector
  • Simon TateDirector
  • Andrew LevinExecutive Officer, Director
  • Aoife BrennanExecutive Officer, Director
  • Judith DunnDirector
  • Valerie MorissetExecutive Officer
Offering amount
$120M
Amount sold
$120M
First sale
Jun 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$60MraisedMay 2021 · 9 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Andrew LevinDirector
  • Erin LavelleExecutive Officer
  • Liam RatcliffeDirector
  • Judith DunnDirector
  • Valerie MorissetExecutive Officer
  • Robert AzelbyExecutive Officer, Director
  • James BucherExecutive Officer
  • Simon TateDirector
  • Adam RosenbergDirector
  • Leone PattersonDirector
Offering amount
$60M
Amount sold
$60M
First sale
May 2021
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5MraisedNov 2020 · 4 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Simon TateDirector
  • James BucherExecutive Officer
  • Adam RosenbergDirector
  • Liam RatcliffeDirector
  • Andrew LevinExecutive Officer, Director
  • Robert AzelbyExecutive Officer, Director
Offering amount
$50M
Amount sold
$5M
First sale
Oct 2020
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$10MraisedOct 2019 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • David-Alexandre GrosDirector
  • Valerie MorissetExecutive Officer
  • Simon TateDirector
  • Andrew LevinExecutive Officer, Director
Offering amount
$10M
Amount sold
$10M
First sale
Oct 2019
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$16.3MraisedOct 2019 · 6 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Simon TateDirector
  • Valerie MorissetExecutive Officer
  • Andrew LevinExecutive Officer, Director
  • David-Alexandre GrosDirector
Offering amount
$16.3M
Amount sold
$16.3M
First sale
Feb 2019
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events
$317Mvaluation at IPOAug 2021 · $12.50/share · 424B4
filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

In the news

ASLAN Pharmaceuticals (NASDAQ:ASLN) & Eliem Therapeutics (NASDAQ:ELYM) Critical Analysis - Ticker Reporttickerreport.com · Jun 2026Eliem therapeutics executive sells over $9,000 in company stock By Investing.cominvesting.com · Sep 2024IPO News: What to look for when Eliem Therapeutics goes public? - Alphastreetnews.alphastreet.com · Aug 2021Seattle's Eliem Therapeutics Raises $60M to Advance Drug Pipeline | Life Science Washingtonlifesciencewa.org · Jun 2021Eliem Therapeutics Announces $60 Million Series B Financingprnewswire.com · May 2021Led by former Juno and Alder exec, Seattle neurology startup Eliem Therapeutics raises $80M – GeekWiregeekwire.com · Mar 2021

Frequently asked questions

What does Eliem Therapeutics do?
Eliem Therapeutics is a clinical-stage biotechnology company developing monoclonal antibodies targeting immune-mediated diseases, with budoprutug, an anti-CD19 antibody designed to deplete B cells in conditions including primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL antibody for IgA nephropathy and related B-cell mediated diseases.
Who are Eliem Therapeutics's investors?
Eliem Therapeutics's investors include Manta Ray Ventures, Access Biotechnology, ACORN BIOVENTURES, RA Capital.
How much funding has Eliem Therapeutics raised?
Eliem Therapeutics has disclosed $363.2M raised across 7 rounds.
Where is Eliem Therapeutics headquartered?
Eliem Therapeutics is headquartered in Wilmington, US.